All News
Understanding Comorbidities in RMD
2026 EULAR Press Release
People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases to cognitive impairment and fractures. The 2026 EULAR Congress showcased new data and ideas around various comorbidities and drug safety issues in people with an RMD – highlighting the need for integrated care. Here are five abstracts to consider.
Read Article
🔬 Does synovial biopsy-guided treatment outperform standard care in PsA?
YES - 68% vs 45% DAPSA remission/LDA in 45pts
OP071 #EULAR2026 @RheumNow https://t.co/cLCR7I8QAm
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#Rosnilimab works!! #PD1 agonist
In #moderate to severe #RA showed fast deep responses in Ph2 #PBO CONTROLLED #rheumatoid #athritis
Seemed NOT to have sig side effects compared to some PD1 drugs that ceased development in RA
#EULAR2026 @RheumNow
#OP0202 #EULARbest https://t.co/Jz92npXdgd
Links:
Janet Pope Janetbirdope ( View Tweet)
SUNSTAR head-to-head after failure of 1 (80+%)–2 prior b/tsDMARDs in RA TCZ vs. ABA
Confirms what we already knew:
-Primary endpoint CDAI change wk26 not different
-Composite response (persistence + low disease activity + low steroid use) 51% vs 35% p=0.034
-Better response in https://t.co/002n3sWtKs
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
Tofacitinib achieved ASDAS inactive disease in 26.4% of patients with early #axSpA (back pain ≤2 years) vs 7.4% placebo at 16 weeks (p=0.006). First RCT of advanced therapy in very early axSpA Abstr#0241 @RheumNow #EULAR2026
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Day 2 of #EULAR2026 Studies to look forward today in #axSpA: new classification criteria performance, sex differences in disease progression, early disease treatment data, primary care education to reduce delays to diagnosis @RheumNow
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
🤰What happens to RA disease activity during pregnancy?
🔴 Most remain stable
🔴 70% with high disease activity at baseline improve
🔴 20% flare again post-partum
✨ACPA+ improve more
✨ Better outcomes after 2016 (after modern treatments)
OP0242 #EULAR2025 @rheumnow https://t.co/i3X566DcN6
Links:
Nelly ZIADE 🍀 Nellziade ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.
Dr. John Cush RheumNow ( View Tweet)
Roc-SpA study
Active axSpA dse + inad response to TNFi ➡️switch or cycled
No significant diff in ASDAS40 at wk24 bet IL-17i & 2nd TNFi
Switching to IL-17i not superior to cycling to 2nd TNFi after inad. response to 1st TNFi
Shared decision is key
AbsOP0235 @RheumNow #EULAR2026 https://t.co/3UP37IEgXv
sheila RHEUMarampa ( View Tweet)
#EULAR2026 OP002 In 20 active #lupus nephritis patients with paired kidney biopsy at baseline & 1 yr, urine proteomics showed histology response correlated with restoration of immune, coagulation and ECM-remodelling pathways. Need to advance this liquid biopsy in clinic @RheumNow https://t.co/KaZSYlA9V1
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
What if we let RA patients choose ttmt?
BACH RCT choice between Filgo / scTNFi vs. standard randomisation
55% JAKi vs 45% TNFi
Higher ttmt satisfaction 46 vs 33 p=0.012
Less ttmt switches 6 vs 15 p=0.026
Less AE reported
Better drug survival
Shared decision making is key! https://t.co/1YS0y6YUEH
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
#OP0236: a look at the revised 2025 ASAS-SPARTAN classification criteria for axSpA from the global CLASSIC cohort. The updated criteria achieved 79.5% sensitivity & 90.4% specificity, with MRI & radiographic sacroiliitis remaining central to classification. #EULAR2026 @RheumNow https://t.co/rVIqyCmB8K
Mrinalini Dey DrMiniDey ( View Tweet)
Is there a ‘window
Of opportunity’ for Rx
#GCA w #IL6i
🤞
Obtain a better response
Rx GCA #GC
#TCZ
#Upadacitinib
#MTX
Study tries to answer if effects of #tocilizumab early vs >8wks is diff
N=471, 19% new GCA
Early vs late TCZ no dif
❎No
Not RCT
POS0624 #EULAR2026 @RheumNow
Janet Pope Janetbirdope ( View Tweet)
#EULAR2026 OP002 More encouraging news in #Sjogren. A Phase II RCT in N=30 patients with ESSDAI=>5 and/or ESSPRI=>5: Anifrolumab (IFN-IR mAb) improved CRESS response vs PBO (80% vs 30%). Impressive effect size for other endpoints too. Need definitive Phase III RCT @RheumNow https://t.co/W3GbA3gKIs
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Does ASA protect against JAKi-associated VTE in #RA? Swedish data (n=26,116): No. JAKi VTE risk remained elevated vs TNFi regardless of concomitant ASA or DOAC use. NSAIDs showed a non-significant trend toward protection. @RheumNow #EULAR2026 POS0068
Jiha Lee JihaRheum ( View Tweet)
COMPARE Trial: CAR-T Cell Rx in 6 refractory active CCP+ RA pts (failed 4-7 prior b/tsDMARDs). After lymphodepletion w/ CTX + fludarabine, B cells depleted w/ neutropenia. Significant drops in CCP, RF, and DAS28, but at wk 12 only 50% ACR 20 response. Encouraging data but not https://t.co/txm32NkOKW
Dr. John Cush RheumNow ( View Tweet)
And we are on!
A full house for #EULAR2026 Opening ceremony highlighting @eular_org initiatives in the field of research, education and patient empowerment and a call “better care leading to better lives” by president Xenofon Baraliakos
@RheumNow https://t.co/zTQUFcjXBI
Aurelie Najm AurelieRheumo ( View Tweet)
It’s that time of year again! 🎉
Delighted to once again be joining the @RheumNow faculty to bring you the highlights from #EULAR2026 in London!
@bella_mehta
@JihaRheum
@AurelieRheumo
@Janetbirdope
@Nellziade
@RHEUMarampa
@synovialjoints
@Yuz6Yusof https://t.co/WvhpYJJNUk
Mrinalini Dey DrMiniDey ( View Tweet)
ACPA and the Transition from Arthralgia to Rheumatoid Arthritis
Patients with clinically suspect arthralgia (CSA), a common prequel to rheumatoid arthritis (RA), showed different patterns of symptoms and progression depending on whether they tested positive for https://t.co/pCaYdEg1gZ
Dr. John Cush RheumNow ( View Tweet)
"the further I look back, the further I can see the future"
Dennis McGonagle quoting Winston Churchill to describe his approach to understanding What is New in PsA at #EULAR2026
@eular_org @RheumNow https://t.co/ayInzzb9lO
Aurelie Najm AurelieRheumo ( View Tweet)
